MOLOGEN AG / Key word(s): Change of Personnel 01.07.2013 15:04 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- MOLOGEN AG: Change within the Supervisory Board - Chairman resigns due to health reasons as announced - successor nominated. Berlin, July 1, 2013 - Dr. Mathias P. Schlichting, member and chairman of the Supervisory Board of MOLOGEN AG, resigned from office today due to health reasons as previously announced. After co-ordination with the remaining members of the Supervisory Board the Executive Board has decided today to nominate Stefan ten Doornkaat, independent lawyer, Düsseldorf, as successor for a term lasting until the ordinary annual general meeting in 2014. The application for the judicial appointment will be filed today. After the appointment the remaining members of the Supervisory Board and Mr ten Doornkaat intend to elect Gregor Kunz as the new Chairman of the Supervisory Board. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: 'First of all we especially thank Dr. Mathias P. Schlichting for his commitment over many years and his fruitful work for MOLOGEN AG. He has advised the company critically and professionally from the very beginning and supported a large number of decisions that significantly contributed to the successful development of the company. Furthermore we are very thankful that he enabled a smooth transition and above all we wish him a good recovery. At the same time we are glad to have won Stefan ten Doornkaat as new member of the Supervisory Board in short notice. With his extensive professional experience as lawyer especially in the field of capital markets and tax he contributes important skills and directly fills the functional gap', says Dr. Matthias Schroff, CEO of MOLOGEN AG About MOLOGEN AG MOLOGEN AG is a publicly listed biotechnology company headquartered in Berlin and specializes in the research and clinical development of innovative drugs in the fields of oncology and infectious diseases. One of the company's most important product candidates is the DNA immunomodulator MGN1703, which is being clinically developed for colorectal cancer and lung cancer. The cell-based cancer therapy MGN1601 for the treatment of renal cancer is also currently at the stage of clinical development.â¨â¨With unique, patented technologies and innovative product developments, MOLOGEN is one of the leading biotechnology companies in the fields of DNA medicine and cell-based therapies.â¨â¨MOLOGEN AG shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI) MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. MOLOGEN AG PRESS SERVICE: Prof. Peter W. Hübner Head of Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 huebner@mologen.com INVESTOR RELATIONS: Jörg Petraà Tel: +49 - 30 - 84 17 88 - 13 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com External Investor Relations: Kirchhoff Consult AG Sebastian Bucher Tel: +49 - 40 - 60 91 86 - 18 Fax: +49 - 40 - 60 91 86 - 16 sebastian.bucher@kirchhoff.de Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation. 01.07.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: MOLOGEN AG FabeckstraÃe 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: info@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------